Toward Ending the HIV Epidemic: Temporal Trends and Disparities in Early ART Initiation and Early Viral Suppression Among People Newly Entering HIV Care in the United States, 2012-2018.
ART initiation
Ending the HIV Epidemic Initiative
epidemiology
health disparity
viral suppression
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
14
04
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
In 2012, the US Department of Health and Human Services updated their HIV treatment guidelines to recommend antiretroviral therapy (ART) for all people with HIV (PWH) regardless of CD4 count. We investigated recent trends and disparities in early receipt of ART prescription and subsequent viral suppression (VS). We examined data from ART-naïve PWH newly presenting to HIV care at 13 North American AIDS Cohort Collaboration on Research and Design clinical cohorts in the United States during 2012-2018. We calculated the cumulative incidence of early ART (within 30 days of entry into care) and early VS (within 6 months of ART initiation) using the Kaplan-Meier survival function. Discrete time-to-event models were fit to estimate unadjusted and adjusted associations of early ART and VS with sociodemographic and clinical factors. Among 11 853 eligible ART-naïve PWH, the cumulative incidence of early ART increased from 42% in 2012 to 82% in 2018. The cumulative incidence of early VS among the 8613 PWH who initiated ART increased from 83% in 2012 to 93% in 2018. In multivariable models, factors independently associated with delayed ART and VS included non-Hispanic/Latino Black race, residence in the South census region, being a male with injection drug use acquisition risk, and history of substance use disorder (SUD; all Early ART initiation and VS have substantially improved in the United States since the release of universal treatment guidelines. Disparities by factors related to social determinants of health and SUD demand focused attention on and services for some subpopulations.
Sections du résumé
Background
UNASSIGNED
In 2012, the US Department of Health and Human Services updated their HIV treatment guidelines to recommend antiretroviral therapy (ART) for all people with HIV (PWH) regardless of CD4 count. We investigated recent trends and disparities in early receipt of ART prescription and subsequent viral suppression (VS).
Methods
UNASSIGNED
We examined data from ART-naïve PWH newly presenting to HIV care at 13 North American AIDS Cohort Collaboration on Research and Design clinical cohorts in the United States during 2012-2018. We calculated the cumulative incidence of early ART (within 30 days of entry into care) and early VS (within 6 months of ART initiation) using the Kaplan-Meier survival function. Discrete time-to-event models were fit to estimate unadjusted and adjusted associations of early ART and VS with sociodemographic and clinical factors.
Results
UNASSIGNED
Among 11 853 eligible ART-naïve PWH, the cumulative incidence of early ART increased from 42% in 2012 to 82% in 2018. The cumulative incidence of early VS among the 8613 PWH who initiated ART increased from 83% in 2012 to 93% in 2018. In multivariable models, factors independently associated with delayed ART and VS included non-Hispanic/Latino Black race, residence in the South census region, being a male with injection drug use acquisition risk, and history of substance use disorder (SUD; all
Conclusions
UNASSIGNED
Early ART initiation and VS have substantially improved in the United States since the release of universal treatment guidelines. Disparities by factors related to social determinants of health and SUD demand focused attention on and services for some subpopulations.
Identifiants
pubmed: 35937648
doi: 10.1093/ofid/ofac336
pii: ofac336
pmc: PMC9348610
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac336Subventions
Organisme : NIAID NIH HHS
ID : K01 AI131895
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2022.
Références
J Assoc Nurses AIDS Care. 2021 Sep-Oct 01;32(5):561-568
pubmed: 33769329
AIDS Patient Care STDS. 2017 Mar;31(3):129-144
pubmed: 28282246
J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):446-453
pubmed: 27391389
AIDS. 2017 Sep 10;31(14):1989-1997
pubmed: 28650383
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
Medicine (Baltimore). 2016 Mar;95(13):e3171
pubmed: 27043679
EClinicalMedicine. 2019 Jul 10;13:101-111
pubmed: 31517267
JAMA. 1998 Nov 4;280(17):1497-503
pubmed: 9809730
PLoS One. 2014 Mar 24;9(3):e92842
pubmed: 24663122
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):23-32
pubmed: 25886926
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):46-50
pubmed: 32379083
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1717-1724
pubmed: 33211683
N Engl J Med. 2009 Apr 30;360(18):1815-26
pubmed: 19339714
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):340-347
pubmed: 27763997
J Infect Dis. 2014 May 1;209(9):1310-4
pubmed: 24218501
JAMA. 2018 Jul 24;320(4):379-396
pubmed: 30043070
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
Int J STD AIDS. 2018 Feb;29(2):147-156
pubmed: 28728527
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):181-7
pubmed: 21857529
AIDS. 2012 Jan 2;26(1):95-103
pubmed: 22008659
Clin Infect Dis. 2013 Nov;57(9):1309-17
pubmed: 23797288
Ann Intern Med. 2012 Sep 4;157(5):325-35
pubmed: 22944874
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
pubmed: 3806354
Clin Infect Dis. 2013 Apr;56(8):1174-82
pubmed: 23315317
Int J Epidemiol. 2007 Apr;36(2):294-301
pubmed: 17213214
Lancet. 2021 Mar 20;397(10279):1095-1106
pubmed: 33617774
AIDS Res Hum Retroviruses. 2021 Oct;37(10):768-775
pubmed: 34030459